RAD51 and colorectal carcinoma: We used the secondary PRISM Repurposing dataset containing cell line drug-perturbation viability screens for 11 topoisomerases and CDK inhibitors tested in eight CRC cell lines (CL34, SNU61, HCC56, LS1034, LS180, HT55, SNUC4, and SW948) that presented similar transcriptional profiles to ReCa signatures.